Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: A local quality improvement initiative

American Journal of Emergency Medicine

Volumn 21, Issue 4, 2003, Pages 302-308

  Fesmire, Francis M ^a,b,d   Peterson, Eric D ^c   Roe, Matthew T ^c   Wojcik, James F ^a,b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b Erlanger Medical Center   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d Emergency Heart Center   (United States)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Glycoprotein IIb IIIa inhibitors; Quality improvement

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG INFORMATION; ELECTROCARDIOGRAM; EMERGENCY WARD; FEEDBACK SYSTEM; FEMALE; HEALTH CARE QUALITY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; THORAX PAIN;

EID: 0043074898     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-6757(03)00027-5     Document Type: Article

References (40)

1. The Epic Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330: 956-961
2. The Capture Investigators: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study [erratum appears in Lancet 1997;350:744]. Lancet 1997;349:1429-1435
3. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
4. The EPISTENT Investigators: Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92
5. The Pursuit Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators: Platelet glycoprotein IIb/ IIIa in unstable angina: Receptor suppression using integrelin therapy. N Engl J Med 1998;339:436-443
6. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [erratum appears in N Engl J Med 1998;339-415]. N Engl J Med 1998;338:1488-1497
7. Boersma E, Akkerhuis M, Theroux P, et al: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes. Circulation 1999;100:2045-2048
8. Gibson M, Murphy SA, Weisberg S, et al: Early initiation of tirofiban therapy before percutaneous intervention associated with improved flow and tissue level perfusion: A TACTICS-TIMI 18 substudy. Circulation 2001;104:548-549 (abstract) (suppl II)
9. Januzzi JL, Hahn SS, Chae CU, et al: Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Am J Cardiol 2000;86:713-717
10. Roe MT, Ohman EM, Bahr R, et al: A randomized, placebo-controlled trial of early administration of epitifibatide for patients with non-ST-segment elevation acute coronary syndromes in the emergency department: The EARLY Pilot Trial. European Heart J 2001;22: 592 (suppl) (abstract)
11. Peterson ED, Canto JG, Pollack CV, et al: Early use of glycoprotein 2b3a inhibitors and outcomes in non-ST-segment elevation MI: Observations from the NRMI-4. J Am Coll Cardiol 2002;39: 303A (suppl A) (abstract)
12. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina), 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf
13. Antman EM, Tanasijevic MJ, Thompson B, et al: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349
14. Ohman EM, Armstrong PW, Christenson RH, et al: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1333-1341
15. De Winter RJ, Koster RW, Schotveld JH, et al: Prognostic value of troponin T, myoglobin, and CK-MB mass in patients presenting with chest pain without acute myocardial infarction. Heart 1996;75:235-239
16. Hamm CW, Goldmann BU, Heeschen C, et al: Emergency room tirage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337: 1648-1653
17. Fesmire FM, Hughes AD, Stout PK, et al: The Erlanger Protocol: A one year experience with serial 12-lead ECG monitoring, 2-hour delta serum marker measurements, and selective dual nuclear scanning to identify and exclude acute coronary syndromes. Ann Emerg Med 2002;40:584-594
18. Fesmire FM, Percy RF, Bardonner JB, Wharton DR, Calhoun FB: Usefulness of automated serial ECG monitoring during the ED evaluation of chest pain patients. Ann Emerg Med 1998;31:3-11
19. Fesmire FM: Which chest pain patients potentially benefit from continuous 12-lead ST-segment monitoring with automated serial ECG. Am J Emerg Med 2000;18:773-778
20. Fesmire FM: A rapid rule out protocol for identification and exclusion of acute myocardial infarction: Continuous 12-lead ECG monitoring in conjunction with the 2-hour ΔCK-MB. Am J Emerg Med 2000;18:698-702
21. Young GP, Gibler WB, Hedges JR, et al: Serial creatinine kinase-MB results are a sensitive indicator of acute myocardial infarction in chest pain patients with non-diagnostic electrocardiograms: The second emergency medicine cardiac research group. Acad Emerg Med 1997;4:869-877
22. Fesmire FM, Percy RF, Bardonner JB, Wharton DR, Calhoun FB: Serial CK-MB testing during the emergency department evaluation of chest pain: Utility of a 2 hour delta CK-MB of +1.6 ng/ml. Am Heart J 1998;136:237-244
23. Fesmire FM: Delta CK-MB outperforms delta Troponin I at 2 hours during the initial ED evaluation of chest pain. Am J Emerg Med 2000;18:1-8
24. Hachamovitich R, Berman DS, Shaw LJ, et al: Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97:535-543
25. Fesmire FM, Hughes AD, Stout PK, et al: Selective dual nuclear scanning in low risk patients with chest pain to reliably identify and exclude acute coronary syndromes. Ann Emerg Med 2001;38:207-215
26. Mehta RH, Sugata D, Tsai TT, et al: Quality improvement initiative and its impact on the management of patients with acute myocardial infarction. Arch Intern Med 2000;160:3057-3062
27. Holmboe ES, Meehan TP, Radford MJ, et al: What's happening in quality improvement at the local hospital: A state-wide study from the Cooperative Cardiovascular Project. Am J Med Qual 2000; 15:106-113
28. Fonarow GC, Gawlinski A: Rationale and design of the cardiac hospitalization atherosclerosis managment program at the University of California Los Angeles. Am J Cardiol 2000;85:10A-17A
29. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al: Effect of local medical opinion leaders on quality of care for acute myocardial infarction: A randomized controlled trial. JAMA 1998;279:1358-1363
30. Mehta RH, Montoye CK, Gallogly M, et al: Improving quality of care for acute myocardial infarction: The guidelines applied in practice (GAP) initiative. JAMA 2002;287:1269-1276
31. Marciniak TA, Mosedale L, Ellerbeck EF: Quality improvement at the national level. Lessons from the Cooperative Cardiovascular Project. Eval Health Prof 1998;21:525-536
32. Every NR, Frederick PD, Robinson M, et al: A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. J Am Coll Cardiol 1999;33:1886-1894
33. French WJ: Trends in acute myocardial infarction management: Use of the National Registry of Myocardial Infarction in quality improvement. Am J Cardiol 2000;85:5B-9B
34. Rogers WJ, Canto JG, Lambrew CT, et al: Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999; The National Registry of Myocardial Infarction 1, 2, and 3. J Am Coll Cardiol 2000;36:2056-2063
35. Bradley EH, Holmboe ES, Mattera JA, et al: A qualitative study of increasing β-blocker use after myocardial infarction: Why do some hospitals succeed? JAMA 2001;285:2604-2611
36. Gillum RF, Fortmann SP, Prineas RJ, et al: International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984;108:150-158
37. WHO MONICA Project: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90: 583-612
38. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36:970-1062
39. Grol R: Improving the quality of medical care: Building bridges among professional pride, payer profit, and patient satisfaction. JAMA 2001;284:2578-2585
40. Hoekstra JW, Pollack CV, Roe MT, et al: Improving the care of patients with non-ST-elevation acute coronary syndromes. Acad Emerg Med 2002;9:1146-1155